Opinion

Video

Contemporary Guidelines for CRM Conditions

Key Takeaways

  • Professional organizations have developed guidelines to manage the interconnectivity of CRM conditions, reflecting advancements in understanding cardiovascular, renal, and metabolic health.
  • Recent updates in guidelines include the integration of novel therapeutic agents and personalized treatment strategies, enhancing evidence-based practices.
SHOW MORE

Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.

Video content above is prompted by the following:

  • How do guidelines from professional organizations, including ACC, AHA, ADA, KDIGO, ACE, and DCRMi, address the management and interconnectivity of CRM conditions?
  • How have these guidelines evolved in recent years? What are the notable guideline updates in recent years?
  • What impact have these guidelines had on the treatment outcomes of patients with CRM conditions?
  • What gaps are there in these guidelines regarding the management of CRM conditions?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo